EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Pinto, Ana Catarina [1 ]
Teixeira, Margarida [1 ]
Bonito, Nuno [1 ]
Jacinto, Paula [1 ]
Ribeiro, Joao [1 ]
Gervasio, Helena [1 ]
机构：
[1] EPE Coimbra, Med Oncol Serv, Portuguese Inst Oncol Francisco Gentil, Coimbra, Portugal
来源：
ANNALS OF ONCOLOGY | 2011年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：v98 / v98
页数：1
相关论文
共 50 条
  • [31] Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) plus FOLFIRI treatment
    Karthaus, Meinolf
    Van Den Eynde, Marc
    Mineur, Laurent
    Thaler, Josef
    Koukakis, Reija
    Berkhout, Marloes
    Gallego, Javier
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [33] SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Barkmanova, Jaroslava
    Petruzelka, Lubos
    Sedlackova, Eva
    Vocka, Michal
    Hejduk, Karel
    Bortlicek, Zbynek
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [34] KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
    Salvatore, L.
    Loupakis, F.
    Fontanini, G.
    Cremolini, C.
    Stasi, I.
    Fabbri, A.
    Ciarlo, A.
    Granetto, C.
    Basolo, F.
    Falcone, A.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [35] KRAS AND BRAF MUTATIONAL ANALYSES IN A PHASE II TRIAL OF FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Salvatore, L.
    Loupakis, F.
    Cremolini, C.
    Lupi, C.
    Masi, G.
    Sensi, E.
    Stasi, I
    Fornaro, L.
    Vasile, E.
    Schirripa, M.
    Truscelli, K.
    Giannini, R.
    Baldi, G. G.
    Altavilla, A.
    Ciarlo, A.
    Granetto, C.
    Fea, E.
    Fontanini, G.
    Basolo, F.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [36] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Bevacizumab plus XELOX as first-line therapy for patients with metastatic colorectal cancer
    Gaspar, E.
    Juarez Marroqui, A.
    Vicent, J.
    Llorca, C.
    Orts, D.
    Galan, A.
    Barrajon, E.
    Cervera Grau, J.
    Giner, V.
    Macia, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] SAFETY AND EFFICACY OF BEVACIZUMAB PLUS STANDARD FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST BEAT
    Van Cutsem, E.
    Berry, S.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Andre, N.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [39] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer
    Akun, E.
    Okutur, K.
    Seber, S.
    Korkmaz, T.
    Aydin, K.
    Bozkurt, M.
    Namal, E.
    Hasbal, B.
    Tecimer, C.
    Demir, G.
    [J]. JOURNAL OF BUON, 2012, 17 (04): : 669 - 676
12345